Company Research Report: Eyestem Research Pvt Ltd

Company Overview

• Company Name: Eyestem Research Pvt Ltd

• Mission: Developing scalable cell replacement therapies for the world. Their goal is to create a scalable cell therapy platform to treat incurable diseases and democratize access to these technologies for the bottom 99% of the global population.

• Founded By:

• Co-founders: Dr. Jogin Desai (Founder & CEO), Dr. Rajani Battu (Co-founder & Chief Medical Officer), Dr. Rajarshi Pal (Co-founder & Chief Scientist), Dr. Dhruv Sareen (Co-founder & Science Officer).

• Key People:

• Dr. Jogin Desai, Dr. Rajani Battu, Dr. Rajarshi Pal.

• Head of Product and Compliance: Vijay Bhaskar Reddy Konala

• Manager - Quality Assurance: Asha Aravind

• Senior QC Analyst: Sudeshna Dhar

• Other team members include several research scientists and fellows.

• Headquarters: No specific location provided for the headquarters.

• Number of Employees: Information not available.

• Revenue: Information not available.

• Company Known For: Known for developing cell therapies, focusing particularly on ophthalmology and other incurable diseases.

Products

Eyecyte-RPETM

• Description: Eyecyte-RPETM is designed to replace lost retinal pigment epithelium cells. It is intended to restore sight for patients in the early stages of Age-Related Macular Degeneration and support vision retention in later stages.

• Key Features:

• Allogenic with sub-retinal injection delivery.

• Promising preclinical results, with ongoing human trials.

• Positioned as one of six global players developing such solutions.

Eyecyte-PRPTM

• Description: This product replaces lost photoreceptor cells and is designed to treat Retinitis Pigmentosa.

• Key Features:

• Extensively tested in animal models.

• Scheduled for further animal testing moving towards clinical stage.

Aircyte-AEC

• Description: Gives patients with Idiopathic Pulmonary Fibrosis a treatment to restore lung function.

• Key Features:

• Delivered via intra-bronchial inhalation.

• Completed proof of concept animal studies and progressing towards clinical testing.

AAV-mediated gene augmentation platform

• Description: A platform aimed at treating inherited retinal dystrophies through gene therapy.

• Key Features:

• Currently focusing on LCA13 gene therapy.

• Preliminary experiments in progress.

Recent Developments

• 2025 Developments:

• Interim data presented on Eyecyte-RPE's safety and efficacy at an ocular research conference.

• 2024:

• Positive recommendation received from DSMB for its dry AMD treatment.

• Human trials commenced for the dry AMD treatment.

• 2023:

• Filed for IND approval for treating geographic atrophy.

• Announced commencement of US operations.

• 2022:

• Raised Series A funding round.

• Awarded Top Innovator at the ET Startup Awards for efforts to make cell therapies more affordable.

Collaborations

• Key Collaborations:

• Partnerships with prominent institutions like Singapore Eye Research Institute and Oregon Health and Science University.

• Collaborations and licensing agreements to advance their stem cell research.

• GMP manufacturing partnerships with top pharmaceutical companies.

Publications

Eyestem has contributed numerous scientific papers on subjects ranging from cell therapy protocols to innovative treatments for retinal and pulmonary conditions. It actively engages with scientific communities through research publications in reputed journals.

Conclusion

Eyestem Research Pvt Ltd is positioned as a leader in cell therapy and regenerative medicine with a global collaborator network. The company's products span treatments for significant ophthalmological and pulmonary conditions, reinforced by robust scientific research and active clinical development stages. They continue to push forward with innovative therapies characterized by affordability and high-quality standards.